HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CGP 74588

a metabolite of STI-571; structure in first source

Also Known As:

CGP-74588; CGP74588

Networked: 10 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrimidines: 510
    - CGP 74588: 10
  - Piperazines: 26
    - CGP 74588: 10

Experts

1.	Chatelut, Etienne: 2 articles (11/2008 - 10/2006)
2.	Delbaldo, Catherine: 2 articles (11/2008 - 10/2006)
3.	Séronie-Vivien, Sophie: 2 articles (11/2008 - 10/2006)
4.	Vassal, Gilles: 2 articles (11/2008 - 10/2006)
5.	Bakhtiar, R: 2 articles (06/2002 - 03/2002)
6.	Hayes, M: 2 articles (06/2002 - 03/2002)
7.	Khemani, L: 2 articles (06/2002 - 03/2002)
8.	Tse, F: 2 articles (06/2002 - 03/2002)
9.	Aichholz, Reiner: 1 article (06/2013)
10.	Blasco, Francesca: 1 article (06/2013)

Related Diseases

1.	Body Weight (Weight, Body) 11/01/2008 - "The apparent clearance of CGP74588 was similarly dependent on both body weight and AGP and significantly lower (30% reduction) at steady-state. " 11/01/2008 - "Plasma imatinib and CGP74588 concentrations observed on day 1 and at steady-state were analyzed by a population pharmacokinetic method (NONMEM) to evaluate the effect of age, body weight, age, sex, albuminemia, plasma alpha1-acid glycoprotein (AGP), and eight polymorphisms corresponding to ABCB1, ABCG2, CYP3A4, CYP3A5, and AGP (pharmacogenetic data available for 46 of 67 patients). "
2.	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 10/15/2006 - "This study explored factors affecting the pharmacokinetic variability of imatinib and CGP 74588, and the pharmacokinetic-pharmacodynamic correlations in patients with advanced gastrointestinal stromal tumors. "
3.	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/01/2011 - "Our results indicate that CGP74588 could hardly positively contribute to the treatment of chronic myeloid leukemia (CML) where ABCB1 gene overexpression represents a possible mechanism of resistance to imatinib in vivo." 06/01/2013 - "Imatinib, a front-line therapy for both chronic myeloid leukemia and of gastrointestinal stromal tumours, is often substantially metabolised via N-demethylation to the significantly less active CGP74588. " 07/01/2006 - "Liquid chromatography-mass spectrometry was used to quantitate imatinib and its metabolite CGP74588 in the plasma and jejunostomy output of a patient with newly diagnosed chronic myelogenous leukemia. " 07/01/2006 - "Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome."
4.	Leukemia 02/01/2009 - "Pharmacokinetic profile of imatinib mesylate and N-desmethyl-imatinib (CGP 74588) in children with newly diagnosed Ph+ acute leukemias." 06/15/2002 - "Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry." 03/05/2002 - "High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry."
5.	Short Bowel Syndrome 07/01/2006 - "Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome."

Related Drugs and Biologics

1.	Imatinib Mesylate (Gleevec)
2.	Cytochrome P-450 CYP3A
3.	ATP-Binding Cassette Transporters (ABC Transporters)
4.	Glycoproteins (Glycoprotein)

Related Therapies and Procedures

1.	Therapeutics
2.	Jejunostomy
3.	Renal Dialysis (Hemodialysis)